AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-4 (canceled)

5. (currently amended) The [[use]] method according to claim [[1]] 17:

[[- of]] wherein said recombinant human erythropoietin such as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of appropriate cells with the help of vectors contained in a nucleotide sequence as described above, recovery of the recombinant protein produced by said cells, and purification,

[[-]] or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and preserving the property of inhibiting the activation of NF-κB.

6-7 (canceled)

8. (currently amended) ~~Products~~ A product containing a compound inhibiting the activation of NF-κB and a cytotoxic molecule adapted to activate the NF-κB factor, as a combined preparation for a simultaneous [[use]] administration, separately or over a long period of time for the treatment of malignant hemopathies and solid tumors.

9. (currently amended) ~~Product~~ The product according to claim 8, characterized in that it comprises as a compound inhibiting the activation of NF-κB, a compound specifically binding to class I cytokine transmembrane receptors in the cells of the organism, selected particularly from growth hormone or erythropoietin.

10. (currently amended) ~~Product~~ The product according to claim 8, characterized in that it comprises:

- human growth hormone, such as obtained by the extraction from hypophysary extracts, and purification,

- or recombinant human growth hormone as encoded by the nucleotide sequence SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human growth hormone whose amino acid sequence is represented by SEQ ID NO 2, said growth hormone being obtained by a transformation of suitable cells with the help of vectors containing a nucleotide sequence such as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2, and keeping the property of the human growth hormone of inhibiting the activation of NF-κB.

11. (previously presented) ~~Product~~ The product according to claim 8, characterized in that it comprises:

- recombinant human erythropoietin as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of suitable cells with the help of vectors containing a nucleotide sequence as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and keeping the property of human erythropoietin of inhibiting the activation of NF-κB.

12. (currently amended) ~~Product~~ The product according to claim 8, characterized in that it comprises as cytotoxic molecule susceptible of activating the NF-κB factor, any molecule selected from the following:

- cytokines,
- anthracyclines including daunomycin and dauxorubicin,
- vinca-alkaloids, including vinblastine and vincristine,
- paclitaxel (or Taxol, DCI).

13. (new) A method for treating a patient with a pathology selected from the group consisting of malignant hemopathies and solid tumors, comprising:

administering to said patient in need thereof an effective amount of a compound that inhibits NF-κB.

14. (new) The method according to claim 13, wherein said compounds are administered to a patient who has become resistant to, or is at risk of developing a resistance to cytotoxic molecules.

15. (new) The method according to claim 13, further comprising administering one or several cytotoxic molecules to treat said pathology and wherein said cytotoxic molecules activate NF-κB factor.

16. (new) The method according to claim 13, wherein said compounds inhibiting the activation of NF-B connected

specifically to transmembranal receptors of cytokines of class 1 cells and are compounds selected from growth hormone or erythropoietin.

17. (new) The method according to claim 13:

wherein said growth hormone is human growth hormone obtained by extraction from hypophysary extracts, and purified,

or recombinant human growth hormone as encoded by the nucleotide sequence SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for the human growth hormone whose sequence in amino acids is represented by SEQ ID NO 2, said growth hormone being obtained by transformation of appropriate cells with the help of vectors containing a nucleotide sequence as described, recovery of the recombinant protein produced by said cells, and purification,

or of any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2,

and preserving the property of human growth hormone of inhibiting the activation of NF-κB.

18. (new) The method according to claim 16, wherein said growth hormone comprises SEQ ID NO 2.

19. (new) The method according to claim 16, wherein said growth hormone is encoded by SEQ ID NO 1.

20. (new) The method according to claim 13, further comprising administering in combination with said compounds, one or several cytotoxic molecules adapted to activate the NF-κB factor selected from the group consisting of cytokines, anthracyclines, daunomycin, dauxorubicin, vinca-alkaloids, vinblastine, vincristine, paclitaxel, Taxel and DCI.

21. (new) The method according to claim 21, characterized in that the dosage of the cytotoxic molecules are administered in combination with said compounds that inhibit NF-κB is about 2 to about 5 times less than the dosage of said cytotoxic molecules administered alone in the scope of treatment of said pathology.